港股異動丨信達生物(1801.HK)漲8% 獲高盛看高至89.8港元
格隆匯3月26日丨信達生物(1801.HK)反彈7.92%,報76.35港元,暫成交3.35億港元,總市值1111億港元。高盛指,信達生物23日盤中曾跌10%,市場憂慮創新PD-1抑制劑達伯舒(Tyvyt)在競爭加劇下今年銷售表現。該行認為市場屬過慮,股價回調亦帶來入市良機。報吿稱,Tyvyt去年已建立強勁醫院覆蓋及醫生認同,維持Tyvyt今年銷售預測34億元人民幣,維持予信達生物“買入”評級,以經風險調整現金流折現率計,目標價由63.1港元升至89.8港元。另外,公司將於3月29日董事會考慮及批准年度業績。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.